AU2017217331B2 - New compositions - Google Patents

New compositions Download PDF

Info

Publication number
AU2017217331B2
AU2017217331B2 AU2017217331A AU2017217331A AU2017217331B2 AU 2017217331 B2 AU2017217331 B2 AU 2017217331B2 AU 2017217331 A AU2017217331 A AU 2017217331A AU 2017217331 A AU2017217331 A AU 2017217331A AU 2017217331 B2 AU2017217331 B2 AU 2017217331B2
Authority
AU
Australia
Prior art keywords
cellulose
active pharmaceutical
pharmaceutical ingredient
drug
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017217331A
Other languages
English (en)
Other versions
AU2017217331A1 (en
Inventor
Albert Mihranyan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2017217331A1 publication Critical patent/AU2017217331A1/en
Application granted granted Critical
Publication of AU2017217331B2 publication Critical patent/AU2017217331B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017217331A 2016-02-12 2017-02-10 New compositions Active AU2017217331B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1602579.3 2016-02-12
GBGB1602579.3A GB201602579D0 (en) 2016-02-12 2016-02-12 New compositions
PCT/GB2017/050345 WO2017137762A1 (en) 2016-02-12 2017-02-10 New compositions

Publications (2)

Publication Number Publication Date
AU2017217331A1 AU2017217331A1 (en) 2018-10-04
AU2017217331B2 true AU2017217331B2 (en) 2022-08-11

Family

ID=55697649

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017217331A Active AU2017217331B2 (en) 2016-02-12 2017-02-10 New compositions

Country Status (8)

Country Link
US (1) US11278563B2 (enExample)
EP (1) EP3413873B1 (enExample)
JP (2) JP7046000B2 (enExample)
KR (1) KR102828449B1 (enExample)
AU (1) AU2017217331B2 (enExample)
ES (1) ES2971977T3 (enExample)
GB (1) GB201602579D0 (enExample)
WO (1) WO2017137762A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109738540A (zh) * 2019-01-28 2019-05-10 山东鲁抗舍里乐药业有限公司 一种非甾体抗炎药非罗考昔含量的测定方法
EP3804701A1 (de) * 2019-10-10 2021-04-14 Bayer AG Verfahren zur herstellung einer pharmazeutischen formulierung mit kristallinen und amorphen anteilen eines wirkstoffes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050053665A1 (en) * 2003-09-08 2005-03-10 Ragnar Ek Nicotine formulations and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0970424A (ja) 1995-07-04 1997-03-18 Takeda Chem Ind Ltd 粒剤の製造法
DK1163234T3 (da) 1999-03-24 2006-02-27 Scherer Technologies Inc R P Farmaceutiske formuleringer med forbedret vandoplöselighed
EP1401503B1 (en) 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
CN101102753A (zh) 2004-12-09 2008-01-09 拉格纳·Ek 包含低结晶度纤维素的药物制剂
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
EP2135601A1 (en) 2008-06-20 2009-12-23 Capsulution Nanoscience AG Stabilization of amorphous drugs using sponge-like carrier matrices

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050053665A1 (en) * 2003-09-08 2005-03-10 Ragnar Ek Nicotine formulations and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CARLSSON D. O. et al., "Aspirin degradation in surface-charged TEMPO-oxidized mesoporous crystalline nanocellulose", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, (2013), vol. 461, no. 1, pages 74 - 81 *
MIHRANYAN A. et al., "Influence of cellulose powder structure on moisture-induced degradation of acetylsalicylic acid", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER, vol. 27, no. 2-3, (2006), pages 220 - 225 *

Also Published As

Publication number Publication date
EP3413873A1 (en) 2018-12-19
JP2022037240A (ja) 2022-03-08
KR20190005826A (ko) 2019-01-16
AU2017217331A1 (en) 2018-10-04
JP2019504866A (ja) 2019-02-21
JP7046000B2 (ja) 2022-04-01
EP3413873B1 (en) 2023-12-27
US11278563B2 (en) 2022-03-22
KR102828449B1 (ko) 2025-07-01
US20190038661A1 (en) 2019-02-07
ES2971977T3 (es) 2024-06-10
EP3413873C0 (en) 2023-12-27
WO2017137762A1 (en) 2017-08-17
GB201602579D0 (en) 2016-03-30
CA3014618A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
Trasi et al. Amorphous solid dispersion formation via solvent granulation–A case study with ritonavir and lopinavir
US20220002306A1 (en) Crystal form of upadacitinib and preparation method and use thereof
Shah et al. Quality-by-design-based development of rivaroxaban-loaded liquisolid compact tablets with improved biopharmaceutical attributes
US11278563B2 (en) Rapid release pharmaceutical formulations containing algal cellulose
CA2934832C (en) Solid preparations containing tofogliflozin and process of producing the same
WO2017216584A1 (en) New compositions
EP1843754A1 (en) New pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance
Zhang et al. The comparison of anticrystallization effects of cellulose derivatives with polyvinylpyrrolidone and poloxamer on andrographolide: In vitro and in vivo characterization
EP3876926A1 (de) Alkohol-antidot
CA3014618C (en) Pharmaceutical composition comprising cellulose and an active ingredient
WO2011078821A1 (en) Effervescent tablet and granule formulation comprising cefixime
CN102526080B (zh) 一种含有水杨酸甲酯乳糖苷的药物组合物、片剂及其制备方法
Wardhana et al. In vitro solubility and release profile correlation with pka value of efavirenz polymorphs
KR20070068658A (ko) 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
Jagtap et al. Acrylic co-polymer and organic acid-based press coated pulsatile tablet of nifedipine using 32 factorial design: use of novel solubilizer for solubility enhancement
RU2681932C2 (ru) Фармацевтическая композиция, содержащая 5-{ 4-(аминосульфонил) фенил} -2,2-диметил-4-(3-фторфенил)-3(2н)-фуранон, и состав в капсулах, содержащий фармацевтическую композицию
Al-Sarraf et al. Dissolution enhancement of telmisartan by liquisolid compacts
Akhlaq et al. Physicochemical characterization and in-vitro evaluation of flubiprofen oral controlled release matrix tablets: Role of ether derivative polymer ethocel
Hangargekar et al. FORMULATION AND IN-VITRO EVALUATION OF BILAYER TABLET CONTAININGZOLMITRIPTAN AND NAPROXEN
WO2016097025A1 (en) Pharmaceutical composition comprising amorphous lenalidomide
Jafer et al. Solubility and Dissolution Enhancement of Lornoxicam by Surface Solid Dispersion
CN101371847B (zh) 拟人参皂苷元在制备抗血小板聚集药物中的应用
CN104257625A (zh) 一种依托度酸胶囊剂及其制备方法
Kotadiya et al. 1. Indukaka Ipcowala College of Pharmacy, New VV Nagar, Gujarat, India. 2. AR College of Pharmacy, VV Nagar, Gujarat, India
US20180008571A1 (en) Oral Pharmacological Composition Including 5--2,2-Dimethyl-4-(3-Fluorophenyl)-3(2H)-Furanone Having Crystalline Structure With Excellent Stability

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)